Woodline Partners LP Acquires 476,032 Shares of Zevra Therapeutics, Inc. $ZVRA

Woodline Partners LP lifted its stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 11.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,615,625 shares of the company’s stock after purchasing an additional 476,032 shares during the quarter. Woodline Partners LP owned 8.44% of Zevra Therapeutics worth $34,571,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently modified their holdings of the company. BNP Paribas Financial Markets purchased a new position in shares of Zevra Therapeutics in the 4th quarter worth about $53,000. GAMMA Investing LLC raised its position in Zevra Therapeutics by 20,564.1% in the 1st quarter. GAMMA Investing LLC now owns 8,059 shares of the company’s stock worth $60,000 after buying an additional 8,020 shares during the last quarter. Squarepoint Ops LLC raised its position in Zevra Therapeutics by 36.1% in the 4th quarter. Squarepoint Ops LLC now owns 16,534 shares of the company’s stock worth $138,000 after buying an additional 4,384 shares during the last quarter. ProShare Advisors LLC purchased a new position in Zevra Therapeutics in the 4th quarter worth about $145,000. Finally, Price T Rowe Associates Inc. MD raised its position in Zevra Therapeutics by 51.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 20,565 shares of the company’s stock worth $172,000 after buying an additional 6,966 shares during the last quarter. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Wall Street Analysts Forecast Growth

ZVRA has been the subject of a number of recent analyst reports. Cantor Fitzgerald boosted their target price on Zevra Therapeutics from $25.00 to $29.00 and gave the stock an “overweight” rating in a research report on Thursday, July 10th. HC Wainwright initiated coverage on Zevra Therapeutics in a research report on Wednesday, July 2nd. They issued a “buy” rating and a $26.00 target price for the company. Zacks Research lowered Zevra Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 18th. Citigroup reissued an “outperform” rating on shares of Zevra Therapeutics in a research report on Wednesday, August 13th. Finally, Wall Street Zen downgraded Zevra Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 20th. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, Zevra Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $23.71.

Insider Transactions at Zevra Therapeutics

In other news, Director John B. Bode bought 5,000 shares of Zevra Therapeutics stock in a transaction that occurred on Tuesday, August 19th. The stock was bought at an average cost of $9.16 per share, with a total value of $45,800.00. Following the acquisition, the director owned 45,000 shares of the company’s stock, valued at $412,200. The trade was a 12.50% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 2.40% of the company’s stock.

Zevra Therapeutics Trading Down 1.4%

Zevra Therapeutics stock opened at $8.21 on Wednesday. The firm has a 50 day moving average of $10.55 and a 200 day moving average of $8.90. The firm has a market capitalization of $460.83 million, a price-to-earnings ratio of -39.10 and a beta of 1.56. Zevra Therapeutics, Inc. has a 12-month low of $6.19 and a 12-month high of $13.16. The company has a current ratio of 7.85, a quick ratio of 7.81 and a debt-to-equity ratio of 0.52.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.